Patents by Inventor Alan G. Barbour
Alan G. Barbour has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6719983Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.Type: GrantFiled: August 16, 2002Date of Patent: April 13, 2004Assignee: Board of Regents, The University of Texas SystemInventors: Steven J. Norris, Jing-Ren Zhang, John M. Hardham, Jerrilyn K. Howell, Alan G. Barbour, George M. Weinstock
-
Publication number: 20040044192Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.Type: ApplicationFiled: August 16, 2002Publication date: March 4, 2004Applicant: Board of Regents, The University of Texas SystemInventors: Steven J. Norris, Jing-Ren Zhang, John M. Hardham, Jerrilyn K. Howell, Alan G. Barbour, George M. Weinstock
-
Publication number: 20030216318Abstract: The present invention is based on the discovery of an arthropod polypeptide which is a homologue of Macrophage Migration Inhibitory Factor (MIF). The present invention relates to the identification and characterization of a homologue of the proinflammatory cytokine, Macrophage Migration Inhibitory Factor in the tick, Amblyomma americanum. The invention provides MIF polypeptide, polynucleodites, antibodies that bind to MIF and methods of use for inducing immunity to ticks, thereby reducing the incidence of tick-borne infections in animals. It should be understood that immunity may also be induced to other species of ticks, including Haemaphysalis spp, Otobius spp, Rhiphicephalus spp, other Ambylomma spp, Dermacentor spp, Ixodes spp and Hyalomma spp and species of Boophilus.Type: ApplicationFiled: April 30, 2003Publication date: November 20, 2003Inventors: Deborah C. Jaworski, Alan G. Barbour
-
Patent number: 6617441Abstract: Bites from Amblyomma americanum, a hard tick, have been associated with a Lyme disease-like illness in the southeastern and south-central United States. Present in 2% of ticks collected in four states were uncultivable spirochetes. Through use of the polymerase chain reaction, partial sequences of the flagellin and 16s rRNA genes of microorganisms from Texas and New Jersey were obtained. The sequences showed that the spirochete was a Borrelia sp. but distinct from other known members of this genus, including B. burgdorferi, the agent of Lyme disease. Species-specific differences in the sequences of the flagellin protein, the flagellin gene and the 16s rRNA gene between the new Borrelia species and previously known species provide compositions and methods for assay for determining the presence of this new spirochete, or for providing evidence of past or present infection by this spirochete in animal reservoirs and humans.Type: GrantFiled: March 24, 1999Date of Patent: September 9, 2003Assignee: Board of Regents University of TexasInventors: Alan G. Barbour, Carol Carter
-
Publication number: 20030092903Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.Type: ApplicationFiled: July 31, 2002Publication date: May 15, 2003Applicant: Board of Regents, The University of Texas SystemInventors: Steven J. Norris, Jing-Ren Zhang, John M. Hardham, Jerrilyn K. Howell, Alan G. Barbour, George M. Weinstock
-
Publication number: 20030060618Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.Type: ApplicationFiled: August 16, 2002Publication date: March 27, 2003Applicant: Board of Regents, The University of Texas SystemInventors: Steven J. Norris, Jing-Ren Zhang, John M. Hardham, Jerrilyn K. Howell, Alan G. Barbour, George M. Weinstock
-
Patent number: 6451769Abstract: Disclosed is a vaccine against Lyme Disease or its causative agent Borrelia burgdorferi (sensu stricto or sensu lato) containing a plasmid a DNA encoding a promoter for driving expression in a mammalian cell, DNA encoding a leader peptide for facilitating secretion/release of a prokaryotic protein sequence from a mammalian cell, a DNA encoding Borrelia OspA or OspB, and a DNA encoding a terminator. Disclosed too is an immunogenic composition against Lyme Disease or its causative agent Borrelia burgdorferi (sensu stricto or sensu lato) containing a plasmid comprising a DNA encoding a promoter for driving expression in a mammalian cell, DNA encoding a leader peptide for facilitating secretion/release of a prokaryotic protein sequence from a mammalian cell, a DNA encoding a Borrelia OspC, and a DNA encoding a terminator. And, methods for making and using such vaccines and the immunogenic composition are also disclosed.Type: GrantFiled: October 15, 1998Date of Patent: September 17, 2002Assignees: Pasteur Merieux Serums et Vaccins, Vical, Inc., The University of Texas SystemInventors: Robert C. Huebner, Jon A. Norman, Xiaowu Liang, Kristin R. Carner, Alan G. Barbour, Catherine J. Luke
-
Patent number: 6437116Abstract: The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the deletion of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.Type: GrantFiled: January 27, 1999Date of Patent: August 20, 2002Assignee: Board of Regents, The University of Texas SystemInventors: Steven J. Norris, Jing-Ren Zhang, John M. Hardham, Jerrilyn K. Howell, Alan G. Barbour, George M. Weinstock
-
Publication number: 20020071847Abstract: All Borrelia burgdorferi sensu lato isolates characterized to date have one or a combination of several major outer surface proteins (Osp). Mutants of B. burgdorferi lacking Osp proteins were selected with polyclonal or monoclonal antibodies at a frequency of 10−6 to 10−5. One mutant that lacked OspA, B, C and D was further characterized in the present study. It was distinguished from the OspA+B+ cells by its (i) auto-aggregation and slower growth rate, (ii) decreased plating efficiency on solid medium, (iii) serum- and complement-sensitivity, and (iv) diminished capacity to adhere to human umbilical vein endothelial cells. The Osp-less mutant was unable to evoke a detectable immune response after intradermal live cell immunization even though mutant survived in the skin the same duration as wild-type cells.Type: ApplicationFiled: October 9, 2001Publication date: June 13, 2002Inventors: Ariadna Sadziene, Alan G. Barbour
-
Patent number: 6300101Abstract: All Borrelia burgdorferi sensu lato isolates characterized to date have one or a combination of several major outer surface proteins (Osp). Mutants of B. burgdorferi lacking Osp proteins were selected with polyclonal or monoclonal antibodies at a frequency of 10−6 to 10−5. One mutant that lacked OspA, B, C and D was further characterized in the present study. It was distinguished from the OspA+B+ cells by its (i) auto-aggregation and slower growth rate, (ii) decreased plating efficiency on solid medium, (iii) serum- and complement-sensitivity, and (iv) diminished capacity to adhere to human umbilical vein endothelial cells. The Osp-less mutant was unable to evoke a detectable immune response after intradermal live cell immunization even though mutant survived in the skin the same duration as wild-type cells.Type: GrantFiled: June 22, 1994Date of Patent: October 9, 2001Assignee: Board of Regents, The University of Texas SystemInventors: Ariadna Sadziene, Alan G. Barbour
-
Patent number: 6296849Abstract: All Borrelia burgdorferi sensu lato isolates characterized to date have one or a combination of several major outer surface proteins (Osp). Mutants of B. burgdorferi lacking Osp proteins were selected with polyclonal or monoclonal antibodies at a frequency of 10−6 to 10−5. One mutant that lacked OspA, B, C and D was further characterized in the present study. It was distinguished from the OspA+B+ cells by its (i) auto-aggregation and slower growth rate, (ii) decreased plating efficiency on solid medium, (iii) serum- and complement-sensitivity, and (iv) diminished capacity to adhere to human umbilical vein endothelial cells. The Osp-less mutant was unable to evoke a detectable immune response after intradermal live cell immunization even though mutant survived in the skin the same duration as wild-type cells.Type: GrantFiled: October 4, 1999Date of Patent: October 2, 2001Assignee: Board of Regents, The University of Texas SystemInventors: Ariadna Sadziene, Alan G. Barbour
-
Patent number: 6203798Abstract: Disclosed and claimed are: substantially pure lipidated OspA protein, compositions containing substantially pure lipidated OspA protein, immunogenic fragments of OspA, compositions containing immunogenic fragments of OspA, polypeptides containing an immunogenic fragment or epitopic region of OspA, and methods for making and using such proteins, fragments, and polypeptides.Type: GrantFiled: June 6, 1995Date of Patent: March 20, 2001Assignee: Symbicom AktiebolagInventors: Sven Bergstrom, Alan G. Barbour, Louis A. Magnarelli
-
Patent number: 6183986Abstract: Disclosed and claimed is an isolated DNA molecule having a nucleotide sequence encoding substantially pure OspA, as well as vectors containing such DNA, uses of such DNA, and compositions containing such vectors.Type: GrantFiled: June 6, 1995Date of Patent: February 6, 2001Assignee: Symbicom AktiebolagInventors: Sven Bergstrom, Alan G. Barbour, Louis A. Magnarelli
-
Patent number: 6083722Abstract: Disclosed and claimed are Lyme disease vaccines and methods for making and using them. The vaccines include a vector containing DNA encoding OspA or an immunogenic fragment thereof or such DNA encoding OspA or an immunogenic fragment thereof which has been modified by substitution, addition, insertion or deletion of one or more nucleotides, whereby the DNA when expressed results in OspA, or an immunogenic fragment thereof, or a polypeptide having the immunological activity of OspA or the fragment thereof.Type: GrantFiled: June 6, 1995Date of Patent: July 4, 2000Assignee: Symbicom ABInventors: Sven Bergstrom, Alan G. Barbour, Louis A. Magnarelli
-
Patent number: 6077515Abstract: This invention relates to flagella-less strains of Borrelia and to novel methods for use of the microorganisms as vaccines and in diagnostic assays. Although a preferred embodiment of the invention is directed to Borrelia burgdorferi, the present invention encompasses flagella-less strains of other microorganisms belonging to the genus Borrelia. Accordingly, with the aid of the disclosure, flagella-less mutants of other Borrelia species, e.g., B. coriacei, which causes epidemic bovine abortion, B. anserina, which causes avian spirochetosis, and B. recurrentis and other Borrelia species causative of relapsing fever, such as Borrelia hermsii, Borrelia turicatae, Borrelia duttoni, Borrelia persica, and Borrelia hispanica, can be prepared and used in accordance with the present invention and are within the scope of the invention.Type: GrantFiled: August 13, 1996Date of Patent: June 20, 2000Assignee: The University of Texas System, Board of RegentsInventors: Alan G. Barbour, Virgilio G. Bundoc, Adriadna Sadziene
-
Patent number: 5932220Abstract: Bites from Amblyomma americanum, a hard tick, have been associated with a Lyme disease-like illness in the southeastern and south-central United States. Present in 2% of ticks collected in four states were uncultivable spirochetes. Through use of the polymerase chain reaction, partial sequences of the flagellin and 16s rRNA genes of microorganisms from Texas and New Jersey were obtained. The sequences showed that the spirochete was a Borrelia sp. but distinct from other known members of this genus, including B. burgdorferi, the agent of Lyme disease. Species-specific differences in the sequences of the flagellin protein, the flagellin gene and the 16s rRNA gene between the new Borrelia species and previously known species provide compositions and methods for assay for determining the presence of this new spirochete, or for providing evidence of past or present infection by this spirochete in animal reservoirs and humans.Type: GrantFiled: May 8, 1995Date of Patent: August 3, 1999Assignee: Board of Regents University of Texas SystemInventors: Alan G. Barbour, Carol Carter
-
Patent number: 5846946Abstract: Plasmid DNA encoding at least one Borrelia genospecies antigen and methods for making and using such a plasmid are disclosed and claimed. The genospecies can be burgdorferi, garinii and/or afzelli. The antigen can be OspA and/or OspB and/or OspC. Compositions containing the plasmid DNA are useful for administration to a host susceptible to Lyme Disease for an in vivo response, such as a protective response, or for generating useful antibodies. The inventive plasmid can also be transfected into cells for generating antigens in vitro. And, the inventive plasmid can be prepared by isolating DNA (such as DNA coding for: promoter, leader sequence, antigen, and terminator) and performing a ligation or ligations, such as a three-way ligation. More particularly, administration of DNA encoding Borrelia genospecies antigen, e.g.Type: GrantFiled: June 14, 1996Date of Patent: December 8, 1998Assignees: Pasteur Merieux Serums et Vaccins, Vical Inc., University of Texas Health Science CenterInventors: Robert C. Huebner, Jon A. Norman, Xiaowu Liang, Kristin R. Carner, Alan G. Barbour, Catherine J. Luke
-
Patent number: 5688512Abstract: Disclosed and claimed are substantially pure OspA, vaccines including substantially pure OspA and an immunologically acceptable carrier or vehicle, methods for producing such vaccines, and methods for inducing a protective immunological response against Borrelia burgdorferi employing such vaccines. The methods for producing the vaccines can include admixing the OspA and the carrier or vehicle. The methods for producing the vaccines also can include recovering the OspA from a host organism transformed with a vector containing DNA encoding the OspA and admixing the OspA with an immunologically acceptable carrier or vehicle. Such methods can further include adding an adjuvant. The vaccine can contain OspA from two or more strains of Borrelia burgdorferi.Type: GrantFiled: January 20, 1995Date of Patent: November 18, 1997Assignee: Symbicom AktiebolagInventors: Sven Bergstrom, Alan G. Barbour
-
Patent number: 5585102Abstract: This invention relates to flagella-less strains of Borrelia to novel methods for use of the microorganisms as vaccines and in diagnostic assays. Although a preferred embodiment of the invention is directed to Borrelia burgdorferi, the present invention encompasses flagella-less strains of other microorganisms belonging to the genus Borrelia. Accordingly, with the aid of the disclosure, flagella-less mutants of other Borrelia species, e.g., B. coriacei, which causes epidemic bovine abortion, B. anserina, which causes avian spirochetosis, and B. recurrentis and other Borrelia species causative of relapsing fever, such as Borrelia hermsii, Borrelia turicatae, Borrelia duttoni, Borrelia persica, and Borrelia hispanica, can be prepared and used in accordance with the present invention and are within the scope of the invention. Therefore, a preferred embodiment comprises a composition of matter comprising a substantially pure preparation of a strain of a flagella-less microorganism belonging to the genus Borrelia.Type: GrantFiled: September 20, 1993Date of Patent: December 17, 1996Assignee: Board of Regents, The University of Texas SystemInventors: Alan G. Barbour, Virgilio G. Bundoc, Adriadna Sadziene
-
Patent number: 5582990Abstract: Disclosed and claimed are isolated nucleic acid molecules, such as DNA encoding Borrelia burgdorferi OspA, vectors containing the nucleic acid molecules, and methods for diagnosing Borrelia burgdorferi infection employing such nucleic acid molecules. The isolated nucleic acid molecule can be an isolated DNA molecule encoding the 31 kD OspA protein of New York strain B31. The isolated nucleic acid molecule also can be an isolated DNA molecule encoding Borrelia burgdorferi OspA and a signal peptide which contains an amino acid recognition sequence. The recognition sequence can be L-z-z-C, where each z independently designates a small, neutral amino acid, such as isoleucine or alanine. The recognition sequence can also be L-I-x-C where x is a non-charged amino acid residue, such as alanine. Further, the isolated nucleic acid molecule can be an isolated DNA molecule encoding Borrelia burgdorferi OspA and which includes a 5'-flanking region containing at least one promoter sequence for expression of the OspA.Type: GrantFiled: October 3, 1994Date of Patent: December 10, 1996Assignee: Symbicom AktiebolagInventors: Sven Bergstrom, Alan G. Barbour, Louis A. Magnarelli